New hope for frail lung cancer patients: immunotherapy shows promise

NCT ID NCT04108026

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tested the drug durvalumab in 50 people with advanced stage IV non-small cell lung cancer who had poor overall health (ECOG 2-3) and had not received prior treatment. The goal was to see if the drug could control the cancer and be safe for these patients, who are often excluded from other trials. The approach uses the immune system to fight the cancer, but patients may need ongoing monitoring or additional treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HM Hopital Nord

    Marseille, France

  • AP-HP Hopital Tenon - Pneumologie

    Paris, 75020, France

  • Besançon - CHU

    Besançon, France

  • CH

    Colmar, France

  • CHR d'Orléans La Source

    Orléans, France

  • CHRU Grenoble

    Grenoble, France

  • CHRU de Lille

    Lille, France

  • CHU Strasbourg

    Strasbourg, France

  • CHU Toulouse - Pneumologie

    Toulouse, France

  • CHU Tours - Pneumologie

    Tours, France

  • Caen - CHU Côte de Nacre

    Caen, 14000, France

  • Centre Hospitalier - Pneumologie

    Le Mans, 72000, France

  • GRH Mulhouse Sud-Alsace

    Mulhouse, France

  • Hôpital Ambroise Paré - Pneumologie

    Boulogne, France

  • Lyon - URCOT

    Pierre-Bénite, France

  • Montpellier - CHRU

    Montpellier, 34295, France

  • Nancy - Institut de Cancérologie de Lorraine

    Nancy, France

  • Nantes - ICO Site René Gauducheau

    Nantes, 44805, France

  • Paris - APHP Bichat

    Paris, France

  • Paris - Curie

    Paris, France

Conditions

Explore the condition pages connected to this study.